Coloplast stock holds firm as earnings growth supports valuation

Coloplast stock is underpinned by steady earnings growth and a rising dividend as the Danish medical device group (ISIN DK0060448595) continues to expand its ostomy and continence care franchises, according to the company’s investor information as of 2025. The shares are listed on Nasdaq Copenhagen, giving the group access to both Nordic and international capital markets.

Revenue climbs above DKK 24 billion

According to Coloplasts published results for the 2023/24 financial year, the company generated revenue of around DKK 24.5 billion for the period, reflecting mid to high single digit organic growth compared with the previous year. This expansion was driven primarily by ostomy care and continence care products, which together account for the majority of group sales. Management highlighted that underlying demand trends remain positive as aging populations and higher chronic disease incidence support procedure volumes.

In the previous financial year 2022/23, Coloplast had reported revenue in the region of DKK 22.9 billion, so the latest figure implies an increase of about DKK 1.6 billion year on year. That translates into a growth rate of roughly seven percent on a reported basis, underscoring the group’s ability to grow faster than many mature medtech peers. The firm also continued to invest in emerging markets, where double digit growth in ostomy and wound care helped offset slower development in some European countries.

Operating profit and margin expand

On the profitability side, Coloplast disclosed that its operating profit (EBIT) for the 2023/24 financial year reached roughly DKK 7.0 billion. This compares with an EBIT level of about DKK 6.3 billion in 2022/23, an increase of around DKK 0.7 billion. The EBIT margin thereby improved from approximately 27.5 percent in 2022/23 to close to 28.5 percent in 2023/24, reflecting efficiency gains, manufacturing scale effects, and a shift toward higher value products.

The firm has repeatedly signaled a long term ambition of sustaining an EBIT margin above 30 percent, and the recent improvement brings it a step closer to that target. Cost discipline and selective price increases contributed to the margin expansion, while higher freight and raw material costs remained a headwind. For investors, the margin trajectory is central because it influences the company’s capacity to fund both research and shareholder returns without stretching the balance sheet.

Dividend growth supports shareholder returns

Coloplast also continued its long standing policy of distributing a substantial portion of earnings through dividends. For the 2023/24 financial year, the board proposed a total dividend of around DKK 23 per share, compared with approximately DKK 21 per share paid for 2022/23. This implies an increase of about DKK 2 per share year on year, or close to 9.5 percent, consistent with historical mid to high single digit dividend growth.

Over the last decade, the company has raised its dividend almost every year, reflecting confidence in the durability of its cash generation. The payout ratio typically falls in a corridor around fifty to sixty percent of net profit, leaving room to finance capital expenditures, selective acquisitions, and product innovation. For long term shareholders, this combination of earnings growth and a rising cash distribution has been a key element of the investment case.

Ostomy care remains the core franchise

Coloplast’s business relies heavily on its ostomy care franchise, which accounts for a significant share of revenue and profit. The group’s latest annual report shows that ostomy products contributed roughly forty percent of total revenue in the 2023/24 financial year, followed by continence care, interventional urology, and wound care. Within ostomy, the company aims to differentiate through comfort, skin protection, and ease of use, which are important for patient quality of life.

Management has pointed to demographic factors as a support for long term demand in ostomy care. Rising incidence of colorectal cancer and inflammatory bowel disease, together with better access to surgery in emerging markets, increases the number of people living with a stoma. Coloplast has invested in training programs for nurses and partnerships with healthcare providers, which can strengthen loyalty and support adoption of higher value product lines.

Innovation and R&D spending underpin growth

To defend its market positions and open new niches, Coloplast invests consistently in research and development. In the 2023/24 financial year, R&D expenses amounted to roughly five percent of revenue, equivalent to around DKK 1.2 billion. This is up from an R&D spend of approximately DKK 1.1 billion, or just under five percent of revenue, in 2022/23. The increase reflects clinical studies, material science development, and digital tools that support patient monitoring and product selection.

New product launches have focused on improved adhesives, more discreet ostomy bags, and devices that reduce leakage and skin irritation. The company has also explored digital platforms that help patients track usage and communicate with healthcare professionals. For investors, the key question is whether these innovations can sustain premium pricing and fend off competition from other global medtech groups and regional manufacturers.

Balance sheet and cash flow allow flexibility

Coloplast’s balance sheet is comparatively conservative for a growth oriented medtech company. At the end of the 2023/24 financial year, net interest bearing debt was equivalent to roughly one times EBITDA, according to company reporting. This level is modest and leaves flexibility for bolt on acquisitions and continued shareholder distributions. In prior years, the group has used its financial strength to expand in adjacent areas such as interventional urology.

Operating cash flow also remained robust. The company generated free cash flow after capital expenditures in the low to mid DKK 5 billion range in 2023/24, broadly in line with the prior year despite higher investment in production capacity and automation. Stable cash conversion supports the sustainability of the dividend policy and provides room to absorb cyclical swings in demand or input costs.

Regulation, pricing, and competition remain key risks

Like other healthcare product manufacturers, Coloplast operates in a highly regulated environment, and reimbursement decisions by public and private payers can influence pricing and volume. Changes in tender structures, reference pricing, or budget constraints in key markets such as Europe may pressure margins if not offset by cost savings or product mix improvements. In some markets, local competitors or hospital own brands can intensify pricing competition, particularly in commoditized wound care categories.

Currency fluctuations also play a role, as Coloplast reports in Danish kroner but generates a large portion of revenue outside Denmark. Movements in the euro, US dollar, and other currencies can impact reported revenue and profit, although the company uses hedging strategies to mitigate short term volatility. Supply chain disruptions and inflation in raw materials such as resins and packaging are additional operational risks that management must navigate.

Representative product: ostomy care appliances

A representative Coloplast product category is its ostomy care appliances, including one piece and two piece systems designed for patients with colostomies, ileostomies, or urostomies. These systems combine skin friendly adhesive plates with discreet bags intended to provide comfort and leak protection over many hours of wear. The company has built out product families that address different body shapes, activity levels, and sensitivities, reinforcing its reputation among specialized nurses and patients.

Coloplast stock and market value

Coloplast stock is traded on Nasdaq Copenhagen under the primary listing, and the company’s market capitalization has in recent periods been in the range of several hundred billion Danish kroner, reflecting its status as one of the largest healthcare issuers in the Nordic region. The shares are included in key indices for the Danish market, making them a core holding for many institutional investors seeking exposure to defensive growth in medical technology.